or
Bookmark and Share
Biomolecular contrast agents for therapy success and dose monitoring in radiation therapy with proton or ion beams
 
   
Document Number
US Patent 7585492
Issued Date
September 8, 2009
Link
Inventors
Map
Abstract
A bio-molecular contrast agent (BMCA) is introduced into a biological organism such that the agent binds or reacts with target tissue within that organism. The BMCA is also signal-giving, and signal reactive, capable of being inactivated by delivery of energy thereto. By monitoring the decrease in signal strength of the BMCA, the actual dosage delivered to the target can be determined and monitored. The decrease in BMCA signal strength can also be correlated to the level of destruction of the target, allowing for determination of therapy success.
Tags:
Description:
Amusing 0%
Clever 0%
Complex 0%
Efficient 0%
Historic 0%
Important 0%
Innovative 0%
Interesting 0%
Practical 0%
Simple 0%
Number of Claims:
24
Comments:
no comments yet
Owner
Published
September 8, 2009
Application Number
10/849,328
Filed
May 18, 2004
US Classification
424/9.1   424/9.6
Int'l Classification
A61K   49/00   (20060101)   A61B   5/00   (20060101)   A61B   8/00   (20060101)  
Assistant Examiner
Attorney/Law Firm
USPTO Field of Search
424/9.1  
Related Patents
Claims
Description
About| FAQs| Terms & Disclaimer| Link to Us| Contact Us